title: Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
abstract: Several studies have suggested that recombinant factor VIIa (rFVIIa) is effective and safe at doses >90 microg kg(-1). In March 2007, the European Medicines Agency approved the use of single-dose rFVIIa 270 microg kg(-1) for the treatment of mild-to-moderate bleeds in haemophilia patients with inhibitors. The aim of this study was to describe the use of single-dose rFVIIa in a real-life setting. In November 2007, seven haemophilia specialists from five European countries convened to share and discuss their experiences with the single-dose rFVIIa regimen within haemophilia A. Case histories of eight patients were discussed in this retrospective study. Six adult and two paediatric patients (age range, 19 months-40 years) were treated with single-dose rFVIIa for a variety of target-joint bleeding, other bleeds and bleeding prevention. Treatment was successful in all the eight cases, with most patients requiring one dose to achieve bleeding resolution. No thrombotic or other safety concerns were raised by single-dose rFVIIa treatment. All patients and physicians preferred single-dose rFVIIa treatment to multiple injections; key benefits of single-dose rFVIIa treatment reported by patients and physicians included improved quality of life, greater convenience and ease of administration, improved compliance, faster control of bleeding, less injection-related pain and faster pain relief. In the patients reported here, single-dose rFVIIa 270 microg kg(-1) appears to be an effective and safe haemostatic treatment that improves the quality of life and convenience of treatment for patients. Such treatment might be of particular benefit for patients with difficult venous access or needle phobia.
authors.affiliation: Centre Régional de Traitement de l'Hémophilie et des Maladies Hémorragiques, CHU de Brest, France. brigitte.pan-petesch@chu-brest.fr
authors.forename: B
authors.initials: B
authors.lastname: Pan-Petesch
authors.forename: P
authors.initials: P
authors.lastname: Laguna
authors.forename: A
authors.initials: A
authors.lastname: Mital
authors.forename: J
authors.initials: J
authors.lastname: Stanley
authors.forename: M F
authors.initials: MF
authors.lastname: Torchet
authors.forename: S Z
authors.initials: SZ
authors.lastname: Salek
authors.forename: P
authors.initials: P
authors.lastname: Salaj
mesh_terms: D000328:Adult; D019774:Blood Coagulation Factor Inhibitors / Q000008:administration & dosage*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005060:Europe; D015942:Factor VIIa / Q000008:administration & dosage*; D006395:Hemarthrosis / Q000188:drug therapy* / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008297:Male; D016896:Treatment Outcome
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D015942:Factor VIIa